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Objective. To examine the effect of diabetes treatment on change of measures of specific cognitive domains over 4 years. Research
Design andMethods.The sample was drawn from a population-based cohort study in Australia (the PATHThrough Life Study) and
comprised 1814 individuals aged 65–69 years at first measurement, of whom 211 were diagnosed with diabetes. Cognitive function
was measured using 10 neuropsychological tests. The effect of type of diabetes treatment (diet, oral hypoglycemic agents, and
insulin) on measures of specific cognitive domains was assessed using Generalized Linear Models adjusted for age, sex, education,
smoking, physical activity level, BMI, and hypertension. Results. Comparison of cognitive function between diabetes treatment
groups showed no significant effect of type of pharmacological treatment on cognitive function compared to diet only group or
no diabetes group. Of those on oral hypoglycaemic treatment only, participants who used metformin alone had better cognitive
function at baseline for the domains of verbal learning, working memory, and executive function compared to participants on
other forms of diabetic treatment. Conclusion. This study did not observe significant effect from type of pharmacological treatment
for diabetes on cognitive function except that participants who only used metformin showed significant protective effect from
metformin on domain of verbal learning, working memory, and executive function.
1. Introduction
Diabetes is a common and complex metabolic disease that
can lead to end-organ damage in almost all vital organs,
including the brain. Cognitive decline and dementia are now
recognized and investigated as diabetes related complica-
tions. Relation between diabetes and cognition may be due
to diabetes specific variables (macrovascular and microvas-
cular changes, impaired glucose metabolism, chronic inflam-
mation, hyperinsulinemia, insulin resistance, or oxidative
stress), cardiovascular risk factors (hypertension, coronary
artery disease), and life style risk factors (smoking, level of
physical activity, and diet) [1–4].
Diabetes treatments including oral hypoglycemic agents
(OHAs) and insulin that minimize disease symptoms and
potentially prevent complications such as cognitive decline
are of growing importance. These treatments may improve
cognitive performance in diabetes participants by address-
ing both vascular and neurodegenerative complications or
through direct drug properties such as anti-inflammatory
effects. Clinical trials have shown that improved glycaemic
control can lead to improvements on self-reported and
objective measures of cognitive functioning [5–7].
Metformin is the most commonly used OHA among
diabetes patients and its mechanisms are to reduce hepatic
glucose output and increase insulin mediated utilization of
glucose in the periphery [8, 9], to restore insulin signalling
pathways, and to improve insulin sensitivity in periph-
eral tissues [10]. Decreasing insulin resistance, normalising
plasma glucose level, reducing adiposity, and reducing the
formation of atherosclerotic plaques are some ofmechanisms
which have been proposed to explain the link between
metformin and protection against neurodegeneration. Apart
from peripheral effects, previous studies have also demon-
strated that metformin has anti-inflammatory and neuropro-
tective effects on the brain [9].
Exogenous insulin is used as a treatment for type 2
diabetes patients when hyperglycaemia is uncontrolled by
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OHAs. As a hormone, insulin has a number of important
functions in the central nervous system in a healthy human
body. Thus, reduced insulin levels and insulin activity may
contribute to a number of pathological processes that charac-
terize Alzheimer’s disease (AD) such as synaptic loss, limited
dendritic arborisation, and memory impairment [11]. There
are, however, controversial reports in the literature on the
effect of insulin alone or in combination with OHA on cogni-
tive function in diabetes. Severalmolecularmechanisms have
been proposed regarding insulin and its protective effects
(glycaemic control) and risks (anabolic effect including
weight gain, inhibition of lipolysis, and enhanced lipogenesis)
on cognition in patients with diabetes [12].
Though many studies have examined diabetes in relation
to cognitive function, very few studies have evaluated the
influence of type of diabetes treatment on the associationwith
multiple cognitive domains in longitudinal cohort studies.
The aim of the present study is to examine the relationship
between type of diabetes treatment on measures of specific
cognitive domains at baseline and cognitive decline over 4
years.
2. Research Design and Methods
2.1. Study Design: PATH Through Life Study. The PATH
Through Life is a longitudinal cohort study of 7485 adults
randomly sampled from the electoral roll of the Australian
Capital Territory and Queanbeyan. This study comprises
three cohorts, young (aged 20–24 years at baseline/Wave 1),
midlife (aged 40–44 years at baseline/Wave 1), and older
(aged 60–64 years at baseline/Wave 1). All three cohorts were
followed up twice at 4 yearly intervals.
2.2. Participants. Thepresent study focuses on the older aged
cohort between the first follow-up in 2005-2006 (Wave 2,
aged 65–69 years; 𝑛 = 2222) and the second follow-up in
2009-2010 (Wave 3, aged 69−72 years; 𝑛 = 1973). Participants
were excluded if they reported a history of stroke (𝑛 = 61) and
epilepsy (𝑛 = 14), had dementia during assessment (𝑛 = 1),
or were on DPP 4 inhibitors or glitazones (𝑛 = 33) and only
on insulin (𝑛 = 14) or if diabetes treatment data was missing
(36) leaving a final sample of 1814. Details of study design
and participants have been described previously [13]. The
Australian National University Ethics Committee approved
the study and all participants gave written informed consent
to be included in this study and for their data to be linked
to Australian Government Pharmaceutical Benefit Scheme
(PBS) data. PBS data on dispensed medications was available
only for first follow-up (Wave 2, treated as baseline in this
study) and second follow-up (Wave 3, treated as follow-up)
as data linkage was only established after first follow-up.
2.3. Measures of Type of Diabetes Treatment. At baseline and
at each follow-up participants were asked to indicate if they
were taking diabetes treatment (yes/no) for the following:
diet and exercise, tablets, and insulin. The PATH dataset is
also linked to the Australian Government Pharmaceutical
Benefit Scheme (PBS) database which records all prescription
medications dispensed in Australia. Data for use of oral
hypoglycemic agents (OHAs) and insulin and duration of
medication use were extracted from the PBS dataset and
linked to PATH.We used information regarding participants’
medication use from two years before the date of first
follow-up interview to the date of the second follow-up
interview. Thus, the variable classifying type of diabetes
treatment included the data from PBS database (for those
on pharmaceutical treatments) as well as self-report data
for diabetes management through life style modification
(diet and exercise). This methodology follows that of other
published studies.
2.4. Measurement of Covariates. Multiple risk factors for
cognitive decline that have also been linked to diabetes
were selected as covariates. These included demographic
factors (age, sex, and years of education) and cardiovascular
factors (hypertension, smoking, physical activity, and obe-
sity). Hypertension was defined as a measured systolic blood
pressure ≥140mmHg, diastolic blood pressure ≥90mmHg,
or self-report of antihypertensive treatment. Smoking status
was obtained from a self-report questionnaire and coded into
the following categories: current smoker, past smoker, and
never smoked. Physical activity was assessed using the UK
Whitehall II study questionnaire and coded into the follow-
ing categories: mild, moderate, and vigorous activity [14].
Anthropometric measures including self-reported height (in
meters) and weight (in kilograms) at each assessment were
used to calculate Body Mass Index (BMI) (kg/m2).
2.5. Assessment of Cognitive Function. Immediate Recall (first
list of California Verbal Learning Test) was used to measure
verbal short-termmemory [15].WechslerMemory Scale-Digit
Span Backward was used to test working memory [16]. Spot-
the-Word (STW) Task was used to assess verbal ability [17].
Symbol-Digit Modalities Test (SDMT) was used to assess
speed of information processing [18]. Simple Reaction Time
(SRT) and Choice Reaction Time (CRT) were also performed
to measure psychomotor speed and information processing
speed. Details are described elsewhere [19]. Trail Making Test,
part A and part B, provided measures of processing speed
and executive function (task switching) [20]. For both tests
(TMT-A and TMT-B) completion time was recorded. Purdue
Pegboard Test (both hands) (PPEG test)was used as a measure
of psychomotor speed [21].
2.6. Statistical Analysis. Statistical analysis was performed
using the IBM SPSS (Version 22). The association between
type of diabetes treatment and performance on each of the
nine different neuropsychological tests was assessed using a
series of Generalized Linear Models (GLZM). First cross-
sectional analysis was conducted to assess the effect of type
of diabetes medication on cognitive function at baseline.
Participants whowere diagnosedwith diabetes or on diabetes
treatment during baseline assessment were included in dia-
betes treatment groups for this analysis.
Then longitudinal analysis was conducted to assess effect
of type of diabetes medication on change of cognitive func-
tion over 4 years. Model 1 adjusted only for the demographic
variables (age, sex, and years of education) and Model 2
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Table 1: Population characteristics according to type of diabetes treatment.
No diabetes (1603) Diabetes (211)
Diet control (74) OHA only (113) Insulin (24)
Age (mean (SD)) 66.6 ± 1.5 66.3 ± 1.5 66.7 ± 1.6 67.3 ± .3
Males (𝑁 (%)) 818 (51.0) 35 (47.3) 63 (55.8) 12 (50.0)
Years of education (mean (SD)) 14.1 ± 2.7 14.0 ± 2.8 13.1 ± 2.6 14.1 ± 2.6
BMI (mean (SD)) 26.4 ± 4.6 29.8 ± 6.2 29.7 ± 5.3 30.4 ± 5.8
Hypertension (𝑁 (%)) 1001 (62.8) 60 (82.2) 99 (87.6) 18 (75.0)
Physical activity (𝑁 (%))
Mild 522 (33.7) 28 (38.4) 45 (41.3) 11 (52.4)
Moderate 783 (50.5) 34 (46.6) 56 (51.4) 10 (47.6)
Vigorous 246 (15.9) 11 (15.1) 8 (7.3) 0 (0)
Smoking (𝑁 (%))
Never 914 (57.1) 27 (36.5) 48 (42.5) 10 (41.7)
Past 573 (35.8) 40 (54.1) 59 (52.2) 13 (54.2)
Current 115 (7.2) 7 (9.5) 6 (5.3) 10 (4.2)
additionally adjusted for selected cardiovascular risk factors:
physical activity, smoking, BMI, and hypertension. In lon-
gitudinal analysis, we compared diabetes treatment groups
with no diabetes participants in total sample and compared
pharmacological treatment groups to life style modification
only group in diabetes only cohort. Two statistical models
were used as described above using the same covariates.
Participants whowere diagnosedwith diabetes or on diabetes
treatment during baseline assessment and during follow-
up were included into diabetes treatment groups. Statistical
significance was kept at 0.01 to minimize type 1 error due to
multiple comparisons.
3. Results
3.1. Population Characteristics. Table 1 describes characteris-
tics of the study population at baseline according to diabetes
treatment type. Participants with diabetes were more likely
to be obese regardless of type of treatment compared to
participants without diabetes. The percentage of participants
with hypertension was higher in the diabetes group and
highest in the OHA group. Participants on pharmacological
treatments for diabetes were less physically active compared
to no diabetes and diet only groups.
At baseline 133 participants were diagnosedwith diabetes.
78 participants developed diabetes during follow-up. In this
cohort we exclude participants who were only on insulin (𝑛 =
14), DPP 4 inhibitors, or glitazone (𝑛 = 33) due to sample
size for each group and no consistent use. There were no
participants on acarbose or byetta in this cohort. Therefore,
participants on OHA are on either SU or metformin.
Participants who reported that they were on OHA and
took OHA according to PBS data were categorised into the
OHA group. Participants who reported that they were on diet
control and whose PBS data did not indicate use of diabetes
medication were allocated to the diet control only group.
Participants on insulin with or without OHA according to
PBS data were allocated to the insulin treatment group.
3.2. Association between Type of Diabetes Treatment and Cog-
nitive Function. Table 2 presents mean values for individual
cognitive test according to treatment group at baseline and
follow-up. When comparing the baseline cognitive function
with no diabetes group, there was no statistical difference
between treatment groups and no diabetes group. When
analysis was limited to diabetes only group, the comparison
wasmade against life stylemodification group andwe did not
identify significant protective effect from OHA or insulin at
baseline.
Then analysis was conducted to examine the effect of
diabetes treatment on cognitive decline over time. There
was no significant effect of type of diabetes treatment on
cognitive function over 4 years compared to diet only group
or compared to no diabetes group. Table 3 presents results
from theGeneralized LinearModels assessing the association
between type of diabetes treatment and cognitive function
(cross-sectional analysis and longitudinal analysis compared
to life style modification group).
3.3. Relation between Metformin and Cognitive Function.
When comparing participants taking metformin only (𝑛 =
23) to those on other forms of treatment (diet, metformin
with other OHAs or insulin, other OHAs, and insulin or
in combination), metformin treatment alone was associated
with significantly higher performance for Immediate Recall
(verbal memory), Digit Span Backward (working memory),
and Trail Making Test part B (executive function) at baseline.
These findings did not change after adjusting for level of phys-
ical activity, smoking, BMI, and hypertension. Results for all
other tests also showed higher performance to be associated
with the metformin only treatment group, although these
results were not statistically significant. In the longitudinal
analysis, participants only on metformin (𝑛 = 76) showed
significant protective effect only on performance for choice
reaction time. Interestingly, findings for other neurological
tests were also in the same direction but there was no
statistical difference. Table 4 presents findings from GLM
analysis for metformin only treatment group.
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Table 2: Association between type of diabetes treatment and cognitive function (mean and SD).
MMSE SDMT Imm. Rec. STW Digit Back. Trail A Trail B PPEG (both hands) SRT CRT
No diabetes (𝑛 = 1603)
Baseline 29.3 (1.2) 50.3 (9.0) 7.1 (2.2) 53.2 (5.2) 5.3 (2.2) 33.9 (10.6) 78.0 (30.4) 10.1 (1.8) .3 (.1) .3 (.1)
Follow-up 29.1 (1.3) 48.3 (9.1) 6.7 (2.3) 53.3 (5.0) 5.1 (2.2) 35.9 (13.2) 83.3 (33.6) 9.5 (1.8) .3 (.1) .3 (.1)
Change −.2 −2.0 −.4 .1 −.2 2.0 5.3 −.6 0 0
Diet only (𝑛 = 74)
Baseline 29.1 (1.1) 49.1 (8.1) 6.8 (1.9) 53.8 (4.6) 5.0 (2.3) 33.9 (11.0) 79.3 (27.3) 10.0 (1.7) .3 (.1) .4 (.1)
Follow-up 29.2 (1.0) 45.6 (9.3) 6.1 (2.2) 53.6 (5.0) 4.7 (1.9) 39.9 (22.9) 85.4 (29.5) 9.2 (1.7) .3 (.1) .3 (.1)
Change .1 −3.5 −.7 −.2 −.3 6.0 6.1 −.8 0 −.1
OHA only (𝑛 = 113)
Baseline 29.1 (1.2) 46.8 (9.6) 6.4 (2.6) 52.5 (5.6) 4.8 (1.9) 36.0 (12.6) 85.6 (37.4) 10.1 (1.9) .3 (.1) .3 (.1)
Follow-up 29.1 (1.1) 44.4 (9.9) 6.5 (2.2) 52.4 (5.5) 4.7 (2.1) 40.1 (16.1) 95.7 (37.0) 9.1 (1.9) .3 (.1) .3 (.1)
Change 0 −2.4 .1 −.1 −.1 4.1 10.1 −1.0 0 0
OHA + ins. (𝑛 = 24)
Baseline 29.2 (1.2) 47.5 (7.5) 5.5 (2.0) 53.4 (4.4) 3.6 (2.4) 42.9 (15.3) 85.2 (24.8) 8.8 (2.2) .3 (.1) .4 (.1)
Follow-up 29.0 (.9) 43.4 (9.0) 5.9 (2.8) 53.2 (4.7) 4.7 (2.1) 46.2 (20.0) 102.1 (39.5) 7.7 (2.1) .3 (.1) .4 (.1)
Change −.2 −4.1 .4 −.2 1.1 3.3 16.9 −1.1 0 0
Note:measures for Trail A, Trail B, SRT, andCRT represent response time.Thus, positive values for change indicate cognitive decline. All othermeasures (SDMT,
Imm. Rec., STW, Digit Back., and PPEG (both hands)) represent number of items completed correctly (negative values for change indicate cognitive decline).
Table 3: Association between type of diabetes treatment and cognitive function (𝛽 weights and SE).
SDMT Imm. Rec. STW Digit Back. Trail A Trail B PPEG (both hands) SRT CRT
Cross-sectional
M1-OHA only .14 (2.01) .61 (.70) −2.19 (.99) −.04 (.59) −2.18 (2.66) 3.67 (7.99) .28 (.38) −.02 (.01) −.00 (.01)
OHA + insulin −1.02 (2.88) −.68 (.70) −4.02 (1.39) .70 (.42) 4.12 (3.79) 16.92 (11.31) −.12 (.54) .01 (.01) .03 (.01)
M2-OHA only −.46 (2.08) .75 (.47) −2.28 (1.01) .57 (.45) −2.76 (2.72) −.99 (6.62) .37 (.40) −.02 (.01) −.02 (.02)
OHA + insulin −.98 (3.01) −.46 (.67) −4.39 (1.46) −.12 (.64) 3.60 (3.94) 15.74 (9.56) −.12 (.58) −.01 (.02) −.02 (.02)
Longitudinal
M1-OHA only 1.15 (.84) .51 (.30) .03 (.34) .31 (.24) −5.20 (3.48) 11.81 (4.63) −.10 (.23) −.01 (.01) −.01 (.01)
OHA + insulin −.3 (1.25) .16 (.44) −.12 (.51) .30 (.35) −3.37 (3.85) 11.81 (6.81) −.76 (.35) .01 (.01) .00 (.01)
M2-OHA only .66 (1.36) .47 (.50) −.04 (.53) .17 (.38) −6.38 (4.12) 3.36 (7.11) −.53 (.35) −.02 (.01) −.04 (.01)
OHA + insulin −1.97 (1.91) .27 (.70) −.38 (.75) .04 (.53) −9.43 (5.88) 16.14 (9.97) −.94 (.550) −.00 (.02) −.03 (.02)
Note: measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive 𝛽 values indicate poorer performance relative to no diabetes group.
All other measures (MMSE, SDMT, Imm. Rec., STW, Digit Back., and PPEG (both hands)) represent number of items completed correctly (negative 𝛽 values
indicate poorer performance).
Model 1 = control for age, sex, and education; W2 cognitive function.
Model 2 = Model 1 + BMI, PA, smoking, and hypertension.
In this sample, there are 49 participants on metformin
and 26 of them took other OHAs or insulin in addition to
metformin. We conducted a similar analysis to compare the
subjects on metformin (𝑛 = 49) to participants who are
on other forms of diabetic medications. In cross-sectional
analysis, the Digit Span Backward test showed significantly
better performance in the metformin group. No association
was observed between metformin treatment and change of
cognitive function over 4 years.
4. Discussion
In this study, we did not observe significant effect from OHA
or OHA with insulin on cognitive function at baseline or
change of cognitive function over 4 years. In this analysis,
participants who used metformin to treat their diabetes
appeared to have better cognitive function at baseline com-
pared to those who used other forms of treatment. This
effect was strongest for the domains of verbal memory,
working memory, and executive function. We also noted
significant protective effect from metformin on performance
for psychomotor speed over 4 years.
Previous studies have found limited evidence for an effect
of type of diabetes treatment on cognitive function. Two
longitudinal studies surveying exclusively women observed
similar scores on cognitive function tests (TICS and a global
score) for participants without diabetes and for partici-
pants in OHA treatment diabetes groups [22, 23]. Another
report from an Australian study observed greater decline
in executive function and global cognition in participants
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Table 4: Association between type of diabetes treatment and cognitive function (𝛽 weights and SE).
MMSE SDMT Imm.Rec. STW
Digit
Back. Trail A Trail B
PPEG
(both
hands)
SRT CRT
Cross-sectional
M1-met. only .03 (.16) 2.04(2.21)
1.26
(.54)∗
.24
(1.15)
1.14
(.45)∗
−3.47
(2.47)
−17.76
(8.68)∗
−.04
(.42) −.00 (.02) −.00 (.01)
M2-met. only .03 (.15) 2.11(2.25)
1.32
(.50)∗∗
.04
(1.16)
1.17
(.47)∗
−3.72
(2.98)
−14.42
(7.06)∗ .14 (.44) −.01 (.02) −.01 (.01)
Longitudinal
M1-met. only −.10 (.16) 1.06(1.47) .24 (.36)
−.33
(.73) .10 (.30)
−3.00
(3.04)
−.70
(5.57) .48 (.30) −.02 (.01) −.03 (.01)
∗
M2-met. only −.04 (.15) 1.21 (.81) .30 (.29) .09 (.32) .43 (.60) −2.72(6.47)
−5.81
(12.10)
−.08
(.56) −.01 (.02) −.03 (.02)
Note: measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive 𝛽 values indicate poorer performance relative to no diabetes group.
All other measures (MMSE, SDMT, Imm. Rec., STW, Digit Back., and PPEG (both hands)) represent number of items completed correctly (negative 𝛽 values
indicate poorer performance).
∗
𝑝 < 0.01, ∗∗𝑝 < 0.001.
Model 1 = control for age, sex, and education; W2 cognitive function.
Model 2 = Model 1 + BMI, PA, smoking, and hypertension.
with diabetes. However, in further analysis, they found
no relationship between treatment types (OHA versus diet
control) and decline in global cognitive function [24]. In
contrast, Elias et al. [25] reported poor cognitive performance
(Wechsler Logical Memory story recall) among participants
with diabetes but found that compared to healthy controls the
insulin treatment group performedmore poorly on cognitive
measures (immediate and delayed verbal memory on the
story recall test and visual memory). Interestingly, perfor-
mance for participants who were treated with oral agents did
not differ from the no diabetes reference group on any of the
7 neuropsychological tests. A report from Women’s Health
Initiative study reported better verbal knowledge among
participants treated with oral medications and reduced psy-
chomotor speed in those using insulin. This study did not,
however, find an effect of type of diabetes treatment on
cognitive decline [26]. Moore et al. examined the effect of
diabetes and of metformin treatment on cognitive function
in the Primary Research in Memory (PRIME) study and
the Australian Imaging, Biomarkers, and Lifestyle (AIBL)
study. Among participants with diabetes, worse cognitive
performance was associated with metformin use (𝑛 = 35)
(after controlling for age, sex, depression, and level of educa-
tion). This study used only MMSE as a measure of cognitive
function and did not control for other treatments used in
conjunction with metformin when analyzing the association
with metformin. This association was not significant after
they adjusted their analysis for serum B12 level [27]. Ng et
al. [28]. (2014) also examined effect of use of metformin (𝑛 =
365) on cognitive function using MMSE in a relatively larger
cohort study. They observed a significant protective effect
of using metformin in both cross-sectional and longitudinal
analyses. This is the only study to date that has adjusted
their analysis for glycaemic control. To the best of authors’
knowledge there are no other studies that have examined
the effect of metformin on level of cognitive function from a
longitudinal cohort study.However, in both the above studies,
participants in the metformin group may have been using
other treatments in conjunction with metformin. Together
with the available evidence, our findings also suggest that
metforminmay have a protective effect on cognitive function
when compared to other treatments.
The present study has some limitations. Even though we
adjusted models for multiple confounding factors we were
unable to adjust models for other important factors for which
measures were not available, including glycaemic control,
plasma insulin level, type of diabetes, duration of diabetes,
and level of renal function. As an example, metformin is
first-line medication for diabetes and is used commonly
when someone has uncomplicated diabetes. Metformin is
contraindicated in advanced kidney disease. Diabetes with
complications needs more than one OHA with or without
insulin to maintain glycaemic control. Level of glycaemic
control and diabetes complications could directly impact on
the level of cognitive function. Therefore the results need
to be interpreted with caution. The PBS data only contains
data for medications dispensed to individuals and adherence
to these medications is not available. We also did not have
data on other factors relating to treatment type (such as
willingness to take medication) and whether diet control was
used alongside OHA and insulin; hence the effect of diet
control on cognition could not be assessed reliably. When
we compared the different types of treatment groups (diet,
OHA, and insulin) sample size for each group was small,
thus reducing statistical power. The duration of follow-up in
the present study is relatively short and this may influence
our findings as the symptoms of cognitive disease have long
duration.Thepercentage of participants with diabetes (11.6%)
in this cohort is slightly less than Australian prevalence rates.
According to the Australian Institute of Health and Welfare
(2007-2008) 14% of the general population aged between
64 and 70 years were diagnosed with diabetes. Therefore,
it is possible that undiagnosed diabetes participants were
included into no diabetes group.
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This study also has several strengths. First the analyses
include data from a large longitudinal cohort. The PATH
Through Life project also provides a unique opportunity to
examine multiple cognitive domains. We were also able to
use a more objective measure of medication use (PBS data)
than self-report as has been used in many prior studies.
Furthermore, a large number of covariates were included in
the analysis.This enabled adjustment for a broad array of con-
founders. Most importantly, to the best of our knowledge this
is the first study that has examined the effect of metformin on
multiple cognitive domains in a longitudinal cohort study.
In summary, we did not find any association between
types of diabetes treatment with cognitive function. In regard
to therapeutic risk assessment, metformin appears to provide
some protection against cognitive function although the
exact mechanisms are unclear and this effect could also be
attributable at least in part to other factors differentiating
the treatment groups. Therefore, adequately powered RCTs
are needed to establish long-term effects of antidiabetic
medications on cognition.
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